[Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
OBJECTIVE
To investigate the relationship between curative effect and incidence rate of the YMDD mutations of hepatitis B virus during lamivudine treatment for chronic hepatitis B patients twenty-four weeks.


METHODS
120 patients with chronic hepatitis B were treated with lamivudine (100 mg/d) over 24 weeks. The levels of serum ALT and HBV-DNA and clinical symptoms were detected at baseline and the 24th weeks after treatment. HBV-DNA YMDD mutation in 17 patients was detected by gene chips at baseline and the 24th weeks.


RESULTS
(1) Beside I case of YMDD/YVDD mutation was found before lamivudine treatment, 7 mutation were found after 24 weeks treatment, 2 with pure mutation strain, one of them was YIDD mutation, and the other was YVDD mutation; 2 and 3 others were YVDD/YMDD mutations and YMDD/YVDD mutations respectively. (2) The serum ALT and HBV DNA levels of YMDD mutation group showed no significantly change compared with normal group at baseline and 24th week.


CONCLUSIONS
The level of serum ALT and HBV DNA showed no significantly changes with the incidence of YMDD mutations at the 24 week treatment
Deng
Hong
H
Department of Infectious Diseases, the Second Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Lv
Ye
Y
Fu
Jie
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D020816:Amino Acid Motifs / Q000235:genetics; D000998:Antiviral Agents / Q000008:administration & dosage*; D004279:DNA, Viral / Q000235:genetics; D004259:DNA-Directed DNA Polymerase / Q000235:genetics; D024882:Drug Resistance, Viral / Q000235:genetics; D005260:Female; D015684:Gene Products, pol / Q000235:genetics; D014644:Genetic Variation; D006515:Hepatitis B virus / Q000235:genetics*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009154:Mutation
D000998:Antiviral Agents; D004279:DNA, Viral; D015684:Gene Products, pol; C066027:P protein, Hepatitis B virus; D019259:Lamivudine; D004259:DNA-Directed DNA Polymerase